Bd onclarity™ hpv assay receives fda approval for use with both bd surepath™ liquid-based pap test and hologic thinprep® pap test

Expands access to bd hpv test that more precisely identifies patients' risk for cervical cancer franklin lakes, n.j. , feb. 21, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced u.s. food and drug administration (fda) market approval for the bd onclarity™ hpv assay to be used with the thinprep® pap test.
BDX Ratings Summary
BDX Quant Ranking